In vitro and in vivo investigations demonstrate that inhibiting Nrf2 increases susceptibility of HCC cells to ferroptosis; therefore, both findings illuminate the p62-Keap1-Nrf2 pathway as a therapeutic target in ferroptosis [36]. The gene discussed is KEAP1; the disease is hepatocellular carcinoma.